Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors.

Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Abstract Text:

Hongbo Yu,Joanna A Gibson,Geraldine S Pinkus,Jason L Hornick,

Podoplanin, recognized by monoclonal antibody D2-40, may be a useful marker for follicular dendritic cell (FDC) tumors. Paraffin sections of 125 dendritic cell, histiocytic, and spindle cell lesions were studied, including 11 FDC tumors, 5 interdigitating dendritic cell tumors, 10 histiocytic sarcomas, 5 Langerhans cell histiocytosis, 5 sinus histiocytosis with massive lymphadenopathy, 5 inflammatory pseudotumors of lymph node or spleen, 9 nodal Kaposi sarcomas, 6 inflammatory myofibroblastic tumors (IMTs), 29 gastrointestinal stromal tumors (GISTs), and 10 cases each of malignant peripheral nerve sheath tumor, leiomyosarcoma, monophasic synovial sarcoma (SS), and solitary fibrous tumor. All FDC tumors and Kaposi sarcomas showed strong immunoreactivity for podoplanin (predominantly membranous). Podoplanin expression was only occasionally observed in the other tumor types, including 7 GISTs (24%), 2 IMTs (33%), and 3 SS (30%), and was generally weak and cytoplasmic. Reactivity for podoplanin was more common in spindle cell GISTs (5/13 [38%]) than in epithelioid or mixed-type GISTs (2/16 [13%]). Podoplanin is a highly sensitive marker for FDC tumors and may be useful to help confirm the diagnosis in conjunction with conventional FDC markers, particularly in the differential diagnosis of dendritic cell and histiocytic lesions.

Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Publishing Authors By Initials

H Yu,JA Gibson,GS Pinkus,JL Hornick,

For similar biological factors: biological markers: tumor markers, biological research abstracts see: biological factors: biological markers: tumor markers, biological research

PUBMED ID PMID:

MEDLINE DATE:

Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of clinical pathology

VOLUME: 128

Page Numbers: 776-82

Journal Abbreviation: Am. J. Clin. Pathol.

ISSN: 0002-9173

DAY: 29

MONTH: Nov

YEAR: 2007

Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370470

Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Keywords Mesh Terms:

KEYWORDS: Tumor Markers, Biological

MESH TERMS: metabolism

Chemical & Substance for Abstract: Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Information

Substance Name: monoclonal antibody D2-40

Registry Number: 0

Grant and Affiliation Information for Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors.

AFFILIATION: Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Clin Pathol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Podoplanin D2-40 is a novel marker for follicular dendritic cell tumors Related Publications

• CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis.
• Chronic alcoholism and the conditioned reflex treatment.
• Clinical studies with the Cendehill strain of attenuated rubella vaccine.
• Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms.
• Effects of acetylated endotoxin in modifying human defense mechanisms.
• Evaluation of antibiotics in a typhoid model.
• Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
• Inflammatory myofibroblastic tumours: where are we now?
• Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors.
• Progenitor cells and vascular disease.